Medical Doctor Program year 2021 Source: CMS Open Payments, 2026 publication

Eric Steele

Ophthalmic Plastic and Reconstructive Surgery Portland, OR Medical Doctor

NPI 1871545145 CMS profile 929093

3375 Sw Terwilliger Blvd, Portland, OR 97239

Open in the dashboard

General payments

$24

1 record reported · program year 2021

Research payments

$0

Paid to them · None reported · program year 2021

Ownership & investment interest

$0

None reported

Through program year 2021, Eric Steele of Portland, OR is reported in the CMS Open Payments database as having received $24 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 1st percentile of Ophthalmic Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2021 General $24 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Steele
  • Ophthalmic Plastic and Reconstructive Surgery median
  • Middle half of Ophthalmic Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Eric Steele were reported at $0. Among 325 Ophthalmic Plastic and Reconstructive Surgery profiles paid that year, the median was $298 and the middle half received between $132 and $820.

Show as a table
Year Eric Steele Ophthalmic Plastic and Reconstructive Surgery median Middle half National median
2019 $0 $182 $73–$467 $163
2020 $0 $125 $41–$412 $114
2021 $24 $173 $52–$538 $132
2022 $0 $237 $78–$809 $149
2023 $0 $291 $103–$776 $160
2024 $0 $304 $108–$822 $164
2025 $0 $298 $132–$820 $169

Breakdown

Who paid General payments · program year 2021
  1. Horizon Therapeutics plc $24 1 payment

Every payment, record by record

What the payments were for General payments · program year 2021
  1. Education $24 1 payment
Products named General payments · program year 2021
  1. TEPEZZA $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

534

Median for Ophthalmology: 891

Drug cost

$5,494

Median for Ophthalmology: $68,233

Branded share of claims

86.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erythromycin Erythromycin Base Brand 235 $2,726
Doxycycline Hyclate Generic 27 $998
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 43 $566
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 149 $344
Doxycycline Monohydrate Generic 12 $318
Ondansetron Odt Ondansetron Brand 21 $263
Fluticasone Propionate Generic 19 $234
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $33
Tramadol Hcl Generic 16 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$166,574

Medicare's payments for the services billed

Medicare patients

302

Average age 75

Services billed

926

189 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 43%
Diabetes 22%
Depression 21%
Chronic kidney disease 19%
Ischemic heart disease 18%
Atrial fibrillation 18%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmic Plastic and Reconstructive Surgery in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record